CN108025005A - 神经退行性疾病的治疗 - Google Patents

神经退行性疾病的治疗 Download PDF

Info

Publication number
CN108025005A
CN108025005A CN201680056062.1A CN201680056062A CN108025005A CN 108025005 A CN108025005 A CN 108025005A CN 201680056062 A CN201680056062 A CN 201680056062A CN 108025005 A CN108025005 A CN 108025005A
Authority
CN
China
Prior art keywords
egfr
inhibitor
inhibitors
gefitinib
suppress
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680056062.1A
Other languages
English (en)
Chinese (zh)
Inventor
皮特·理查森
理查德·米德
劳拉·费拉约洛
肯尼思·帕特里克·马尔瓦尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bo Shan Artificial Intelligence Biological Technology Co Ltd
Original Assignee
Bo Shan Artificial Intelligence Biological Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bo Shan Artificial Intelligence Biological Technology Co Ltd filed Critical Bo Shan Artificial Intelligence Biological Technology Co Ltd
Publication of CN108025005A publication Critical patent/CN108025005A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201680056062.1A 2015-09-24 2016-09-23 神经退行性疾病的治疗 Pending CN108025005A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1516905.5 2015-09-24
GBGB1516905.5A GB201516905D0 (en) 2015-09-24 2015-09-24 Treatment of Neurodegenerative diseases
PCT/GB2016/052970 WO2017051188A1 (en) 2015-09-24 2016-09-23 Treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
CN108025005A true CN108025005A (zh) 2018-05-11

Family

ID=54544061

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680056062.1A Pending CN108025005A (zh) 2015-09-24 2016-09-23 神经退行性疾病的治疗

Country Status (13)

Country Link
US (1) US20180263992A1 (enExample)
EP (1) EP3352759A1 (enExample)
JP (1) JP6893917B2 (enExample)
KR (1) KR20180056695A (enExample)
CN (1) CN108025005A (enExample)
AU (1) AU2016329005A1 (enExample)
BR (1) BR112018005855A2 (enExample)
CA (1) CA2999390A1 (enExample)
EA (1) EA201890647A1 (enExample)
GB (1) GB201516905D0 (enExample)
MA (1) MA42930A (enExample)
MX (1) MX2018003619A (enExample)
WO (1) WO2017051188A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113694047A (zh) * 2021-08-31 2021-11-26 杭州师范大学 β-石竹烯在制备抗肿瘤药物中的应用
WO2025152803A1 (zh) * 2024-01-17 2025-07-24 四川大学 一种靶向traf6的多肽及其用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016077595A1 (en) 2014-11-12 2016-05-19 The General Hospital Corporation Methods for treating neurodegenerative diseases
GB201714307D0 (en) * 2017-09-06 2017-10-18 Benevolentai Ltd Treatment of neurodegenerative diseases
GB201714311D0 (en) * 2017-09-06 2017-10-18 Benevolentai Ltd Treatment of neurodegenerative diseases
GB201714316D0 (en) * 2017-09-06 2017-10-18 Benevolentai Ltd Treatement of neurodegenerative diseases
GB201714303D0 (en) * 2017-09-06 2017-10-18 Benevolentai Ltd Treatment of neurodegenerative diseases
CN108853111B (zh) * 2018-08-07 2020-06-05 浙江大学 一种组合物在制备治疗吉非替尼肝脏毒性药物中的应用
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100130493A1 (en) * 2002-08-09 2010-05-27 Stephen Robert Wedge Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US257403A (en) * 1882-05-02 Electric lighting apparatus
US62342A (en) * 1867-02-26 Improved tool for the manufacture of paper bags
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
CA2484797A1 (en) * 2002-05-06 2003-11-13 Washington University Methods of treatment of glaucoma and other conditions mediated by nos-2 expression via inhibition of the egfr pathway
JP4328500B2 (ja) * 2002-07-25 2009-09-09 独立行政法人農業・食品産業技術総合研究機構 中枢神経細胞突起再生剤及びその薬理作用を有する高機能性製品
JP2006522124A (ja) * 2003-04-03 2006-09-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用な組成物
ES2673158T3 (es) * 2004-02-09 2018-06-20 Mitsubishi Tanabe Pharma Corporation Nuevo agente terapéutico para la esclerosis lateral amiotrófica (ELA) o enfermedad atribuible a ELA
RU2405566C9 (ru) * 2005-02-03 2012-04-27 Дзе Дженерал Хоспитал Корпорейшн Способ лечения рака, устойчивого к гефитинибу
US7449442B2 (en) * 2005-07-12 2008-11-11 Children's Medical Center Corporation EGFR inhibitors promote axon regeneration
JP2008061505A (ja) * 2006-09-04 2008-03-21 Hisamitsu Pharmaceut Co Inc 筋萎縮性側索硬化症の治療剤のスクリーニング方法
US8993615B2 (en) * 2008-08-08 2015-03-31 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
CN102573500A (zh) * 2009-08-06 2012-07-11 纽拉尔图斯制药公司 巨噬细胞相关疾病的治疗
EP2490698A4 (en) * 2009-10-22 2013-09-25 Hoffmann La Roche MODULATION OF AXONES DEGENERATION
WO2014018932A2 (en) * 2012-07-27 2014-01-30 Bunt Antonius Martinus Gustave Effluz inhibitor compositions and methods of treatment using the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100130493A1 (en) * 2002-08-09 2010-05-27 Stephen Robert Wedge Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MINGSHAN NIU ET AL: ""Structural bioinformatics-based identification of EGER inhibitor Gefitinib as a putative lead compound for BACE"", 《CHEM BIOL DRUG DES》 *
STINA SYVANEN ET AL: ""Advances in pet imaging of P-Glycoprotein function at the blood-brain barrier"", 《ACS CHEMICAL NEUROSCIENCE》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113694047A (zh) * 2021-08-31 2021-11-26 杭州师范大学 β-石竹烯在制备抗肿瘤药物中的应用
WO2025152803A1 (zh) * 2024-01-17 2025-07-24 四川大学 一种靶向traf6的多肽及其用途

Also Published As

Publication number Publication date
MA42930A (fr) 2018-08-01
CA2999390A1 (en) 2017-03-30
GB201516905D0 (en) 2015-11-11
US20180263992A1 (en) 2018-09-20
JP2018534259A (ja) 2018-11-22
KR20180056695A (ko) 2018-05-29
EA201890647A1 (ru) 2018-09-28
JP6893917B2 (ja) 2021-06-23
EP3352759A1 (en) 2018-08-01
AU2016329005A1 (en) 2018-04-19
WO2017051188A1 (en) 2017-03-30
MX2018003619A (es) 2018-08-01
BR112018005855A2 (pt) 2018-10-16

Similar Documents

Publication Publication Date Title
JP6893917B2 (ja) 神経変性疾患の処置
KR102318306B1 (ko) 암의 치료를 위한 조합 요법
US10434100B2 (en) Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes
TW201141864A (en) Methods for treating viral conditions
ES2962526T3 (es) Secretagogos PAR-4 para el tratamiento del cáncer
Dabouz et al. An allosteric interleukin-1 receptor modulator mitigates inflammation and photoreceptor toxicity in a model of retinal degeneration
CN110652514A (zh) 第三代egfr抑制剂的制药用途
KR20210013155A (ko) 종양 질환 치료용 약제의 제조에서 egfr 억제제와 조합된 cdk4/6 억제제의 용도
CN114246864B (zh) Csf1r激酶抑制剂及其用途
US20180325925A1 (en) Composition for prevention or treatment of neuroinflammatory disease, containing protein tyrosine phosphatase inhibitor
WO2019048852A1 (en) TREATMENT OF NEURODEGENERATIVE DISEASES
US20210069189A1 (en) Treatment of neurodegenerative diseases
US6727260B2 (en) Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders
US9511068B2 (en) Composition for treating or preventing diseases caused by vascular permeability, containing imatinib or pharmaceutically acceptable salt thereof as active ingredient
US20220008409A1 (en) Cancer combination therapy using quinoline carboxamide derivative
US20230165873A1 (en) Methods of Use for Single Molecule Compounds Providing Multi-Target Inhibition to Treat Covid 19
Garcia et al. IL-8 receptor signaling as a novel target for angiogenic retinopathies
WO2019048851A1 (en) TREATMENT OF NEURODEGENERATIVE DISEASES
WO2019048853A1 (en) TREATMENT OF NEURODEGENERATIVE DISEASES
US20240165113A1 (en) Methods of treatment for leukemia
JPWO2019230595A1 (ja) びまん性胃癌の治療剤
CN120346202A (zh) Ripk1抑制剂及其在治疗神经功能障碍中的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20220429

AD01 Patent right deemed abandoned